Pharmaceuticals / The Company recorded 18.8 million in extraordinary income.

The pharmaceutical grew 53.5% more in the United States and barely 0.1% in Europe.

The dermatology division grew by 21.6%, representing 42.5% of revenues.

The profit of pharmaceutical Almirall soared 70.9% to 73.3 million euros in the first nine months of the year. The increase was mainly due to the evolution of the dermatology division in the United States and 18.8 million in extraordinary income.

The Gallardo family company achieved a revenue increase of 1.6% to 595.3 million. The operating result showed an increase of 13% to 172.6 million.

The dermatology division, the company’s main commitment, was the only division to grow.

It recorded an increase in turnover of 21.6%. Currently it already accounts for 42.5% of the group’s sales. The increase occurred mainly in the US market, helped by the euro-dollar exchange rate, and was 53.5%.

Meanwhile, in Europe growth was almost testimonial, only 0.1%. This division sells more in the US than in the Old Continent. Likewise, the company also recorded an increase in extraordinary income. This is 18.8 million from the completion of a milestone associated with Duaklir, a drug from its former respiratory business, transferred to AstraZeneca in the summer of 2014. Almirall expects to close the year with revenues of between 740 and 770 million euros. The EBIT will be between 100 and 130 million. On the Stock Exchange, the pharmaceutical yesterday fell 2.34% to 17.1 euros per share.

Source and photo: Expansion